Skandinaviska Enskilda Banken (SEB)
BHVN

Skandinaviska Enskilda Banken (SEB)’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-92
Closed -$14K – 946
2022
Q3 		$14K Sell
92
-52,454
-100% -$7.77M ﹤0.01% 875
2022
Q2 		$7.66M Sell
52,546
-78,640
-60% -$10M 0.06% 287
2022
Q1 		$15.6M Sell
131,186
-23,914
-15% -$2.98M 0.09% 206
2021
Q4 		$21.4M Sell
155,100
-19,318
-11% -$2.46M 0.11% 169
2021
Q3 		$24.2M Sell
174,418
-3,075
-2% -$384K 0.13% 157
2021
Q2 		$17.2M Buy
177,493
+57,957
+48% +$4.7M 0.11% 192
2021
Q1 		$8.17M Buy
+119,536
New +$9.67M 0.05% 306

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s BHVN Position: Q4 2022 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 92 shares — an estimated $14K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in BHVN in Q1 2021 and held it in 7 quarters. The position peaked at $24.2M in Q3 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 92 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $14K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2021 and held it in 7 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Biohaven Pharmaceutical Holding Company Ltd. position peaked at $24.2M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2022, filed 8 Feb 2023.